Home HOMEPAGE   Fri, 03/29/2024 GMT + 7
    Q & A   Site map Forum   Site map Sitemap   E-mali Contact   Vietnamese Vietnamese
IMPE-QN
Web Sites & Commerce News - Events
Web Sites & Commerce Introduction
Web Sites & Commerce Collaborative activities
Web Sites & Commerce Training
Web Sites & Commerce Specific research studies
Web Sites & Commerce Publications
Web Sites & Commerce Mass organization activities
Web Sites & Commerce Legal documents
Web Sites & Commerce Statistical data
Web Sites & Commerce Work safety
Web Sites & Commerce Vietnam`s Physicians
Finance & Retail Malariology
Epidemiology
Malaria parasitology
Entomology
Diagnosis and Treament
Antimalarial drugs and drug resistant parasites
Malaria Vaccines
Health education and communication
Molecular - biology
Web Sites & Commerce Helminthology
Web Sites & Commerce Other vector-borne diseases

SEARCH

LOGIN
Username
Password

WEBLINKS
Other links

Visiting users: 27
5 2 5 3 0 7 1 4
Online
2 7
 Malariology Diagnosis and Treament
An estimated 32 million women who become pregnant each year can benefit from preventive therapy
LSTM study leads WHO to update its malaria prevention policy

             A study led by Liverpool School of Tropical Medicine (LSTM) has been a critical element in helping the World Health Organization (WHO) to update its policy recommendation o­n intermittent preventive treatment for the prevention of malaria in pregnant women (IPTp) who live in malaria-endemic regions of sub-Saharan Africa.

 

Study results show that when these pregnant women receive three or more doses of preventive therapy instead of the standard two-dose regimen the birth weight of their newborns will be higher. Results of the study have been published by the Journal of the American Medical Association (JAMA) o­n 13 February 2013.1

'Malaria in pregnancy can have devastating consequences for both mother and baby', said Dr. Kassoum Kayentao, the lead author of the study based in Bamako, Mali.'The updated recommendation of the malaria prevention policy from WHO is very good news as it will greatly benefit pregnant women throughout Africa. The new regimen significantly reduces the risk of malaria and malaria-associated severe anaemia in the mother and the risk of low birth weight in the newborn. By increasing a baby?s birth weight, their chances of survival are improved and will lead to better health in their first year of life.'

The study consisted of a meta-analysis of seven randomised controlled trials amongst pregnant women in Africa. Each of these trials compared the standard two-dose regimen with regimens providing the drug more frequently. Combining the outcomes from these seven trials, four of which were published as recently as 2010, results in greater statistical power than provided by the trial outcomes individually. It provides definitive evidence of the benefit o­n birth weight when providing three or more doses of anti-malaria drugs throughout the pregnancy instead of two doses.

The study shows that by providing the drug sulphadoxine-pyrimethamine (SP) more frequently during pregnancy, a period in a woman's life when she and her baby are particularly vulnerable to harmful effects of malaria, the period of protection is greatly enhanced and the risk of malaria re-infection in women is reduced.

'The outcomes of the study were remarkably consistent across Africa, despite differences in malaria transmission, study designs and different degrees of resistance to the drug SP', said Prof. Feiko ter Kuile and senior author of the LSTM-led study. 'We were pleasantly surprised by the consistency and magnitude of the beneficial effect that can be achieved by providing these additional doses during the last 10 weeks of pregnancy, which is a critical period for foetal growth', Prof. Ter Kuile added.

The study comes at a critical time of increasing parasite resistance to SP, leading to questions from malaria-endemic countries regarding the continued effectiveness of IPTp. The findings of the study were presented to the Malaria Policy Advisory Committee of the WHO in September 2012, contributing to an updated policy recommendation o­n intermittent preventive treatment of malaria in pregnancy (IPTp), which is now being communicated to African Member States of the WHO.

'This updated policy will benefit pregnant women in the 36 malaria endemic countries in sub-Saharan Africa which have adopted IPTp with SP as national policy,' said Dr. Robert Newman, Director of the WHO Global Malaria Programme.

Dr. Newman added that the WHO was hopeful that the updated malaria prevention policy could also contribute to increased uptake and quality of antenatal care services in Africa. The adapted protocol is now more closely aligned to WHO's Focussed Antenatal Care (FANC) schedule, ensuring that intermittent preventive treatment with SP can be given to pregnant women during each scheduled ANC visit, improving both maternal and neonatal outcomes.

_____________________________

1JAMA. 2013;309(6):594-604

03/06/2013
(Source: http://www.lstmliverpool.ac.uk)  

Announcement

LIBRARY
Book
Magazine
Document
Photos
Thesis
Documentary form
Research studies
PROFFESSIONAL SOFTWARE
Malaria forecast & management
Document management
Personel management
LEGAL DOCUMENTS
Law
Decision
Decree
Instruction
Circular
Official document
Reports
Others
SPECIFIED IMFORMATION
Malaria facts
Malaria epidemic
Petechial fever
HEALTH SERVICES
Hospital & medical centre
Drugstore
Surgery
Your doctor

Institue of Malariology Parastology and Entomology Quy Nhon
Address: 611B Nguyen Thai Hoc Str,. Quy Nhon City
Tel: (84) 056 846571 Fax: (84) 056 846755
• Designed by Quang Ich JSC